![In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications - ScienceDirect In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2589004221015194-fx1.jpg)
In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications - ScienceDirect
![American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings - Endocrine Practice American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings - Endocrine Practice](https://www.endocrinepractice.org/cms/attachment/3a8cc399-770d-4b1c-bb4f-90c14911a710/gr1.jpg)
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings - Endocrine Practice
![PDF) The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study PDF) The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study](https://i1.rgstatic.net/publication/333800621_The_burden_of_non-alcoholic_steatohepatitis_NASH_among_patients_from_Europe_A_real-world_patient-reported_outcomes_study/links/5e42d55c299bf1cdb91fa8d0/largepreview.png)
PDF) The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study
![First Wave of Novel Drugs for NASH Does Not Live Up to Expectations, Clinical Pharmacy Service's Pipeline Monitoring Team Finds | ForHealth Consulting First Wave of Novel Drugs for NASH Does Not Live Up to Expectations, Clinical Pharmacy Service's Pipeline Monitoring Team Finds | ForHealth Consulting](https://forhealthconsulting.umassmed.edu/wp-content/uploads/2022/12/NASH.png)
First Wave of Novel Drugs for NASH Does Not Live Up to Expectations, Clinical Pharmacy Service's Pipeline Monitoring Team Finds | ForHealth Consulting
![What's in a name? Renaming 'NAFLD' to 'MAFLD' - Fouad - 2020 - Liver International - Wiley Online Library What's in a name? Renaming 'NAFLD' to 'MAFLD' - Fouad - 2020 - Liver International - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/cb84ed96-620a-4937-bbd3-007dbff23aef/liv14478-fig-0001-m.jpg)
What's in a name? Renaming 'NAFLD' to 'MAFLD' - Fouad - 2020 - Liver International - Wiley Online Library
![From NASH to HCC: current concepts and future challenges | Nature Reviews Gastroenterology & Hepatology From NASH to HCC: current concepts and future challenges | Nature Reviews Gastroenterology & Hepatology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41575-019-0145-7/MediaObjects/41575_2019_145_Fig1_HTML.png)
From NASH to HCC: current concepts and future challenges | Nature Reviews Gastroenterology & Hepatology
![IJMS | Free Full-Text | Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC IJMS | Free Full-Text | Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC](https://www.mdpi.com/ijms/ijms-22-04495/article_deploy/html/images/ijms-22-04495-g001.png)
IJMS | Free Full-Text | Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
![New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis | SpringerLink New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs43440-019-00020-1/MediaObjects/43440_2019_20_Fig1_HTML.png)
New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis | SpringerLink
![Frontiers | Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment Frontiers | Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment](https://www.frontiersin.org/files/Articles/615978/fmed-08-615978-HTML/image_m/fmed-08-615978-g001.jpg)